US Patent

US8252813 — Salt and crystalline forms thereof of a drug

Method of Use · Assigned to Abbott Laboratories · Expires 2026-10-02 · 0y remaining

Vulnerability score 80/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent discloses a crystalline form of delafloxacin meglumine and methods for making it, as well as compositions and treatment methods using it.

USPTO Abstract

A crystalline form of a drug, ways to make it, compositions containing it and methods of treatment of diseases and inhibition of adverse physiological events using it are disclosed.

Drugs covered by this patent

delafloxacin-meglumine (DELAFLOXACIN MEGLUMINE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2028`	—	delafloxacin-meglumine
`U-2028`	—	delafloxacin-meglumine

Patent Metadata

Patent number: US8252813
Jurisdiction: US
Classification: Method of Use
Expires: 2026-10-02
Drug substance claim: No
Drug product claim: Yes
Assignee: Abbott Laboratories
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.